Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19934329 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL30891555 | 0.88 | CHRM2 (0.43) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL6653691 | 0.86 | CHRM2 (0.52) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL10449210 | 0.86 | CHRM2 (0.52) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL14141163 | 0.86 | CHRM2 (0.52) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL18250835 | 0.81 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL8425951 | 0.81 | CHRM2 (0.44) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL12990820 | 0.81 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL24854738 | 0.81 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL8460680 | 0.81 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037586-B2 | 4′-phosphate analogs and oligonucleotides comprising the same | DICERNA PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037586-B2 | 4′-phosphate analogs and oligonucleotides comprising the same | RNGTT, DERA, MTAP | CHRM2 4885/4885CHRM1 4878/4885CHRM4 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.